Leviliv 750 Tablet contains Levetiracetam 750 mg, an antiepileptic drug indicated for the treatment of partial-onset seizures, myoclonic seizures, and primary generalized tonic-clonic seizures in patients with epilepsy. Levetiracetam acts by modulating synaptic neurotransmitter release through binding to the synaptic vesicle protein SV2A, thereby stabilizing neuronal activity and reducing seizure frequency. This medication is typically used as adjunctive therapy in adults and pediatric patients aged four years and above. Leviliv 750 Tablet is administered orally, with dosage individualized based on patient response and tolerability. Common adverse effects may include somnolence, dizziness, headache, and behavioral changes such as irritability or mood swings. It is important to monitor patients for any neuropsychiatric symptoms during treatment. Levetiracetam has a favorable pharmacokinetic profile with minimal drug interactions, making it suitable for use in combination with other antiepileptic agents. Caution is advised in patients with renal impairment, necessitating dose adjustment. Leviliv 750 Tablet should be used under strict medical supervision, with adherence to prescribed dosing to optimize seizure control and minimize adverse effects. Discontinuation should be gradual to prevent seizure exacerbation.